L-Dopa dyskinesias

Medication-Induced Movement Disorders

Volumn , Issue , 2015, Pages 110-130

  Ramirez Castaneda, Juan ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84953407847     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781107588738.012     Document Type: Chapter

References (182)

1. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trends in neurosciences 2000;23:S2-7.
2. Olanow CW. The scientific basis for the current treatment of Parkinson’s disease. Annual review of medicine 2004;55:41-60.
3. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet neurology 2009;8:1140-1149.
4. Nutt JG, Chung KA, Holford NH. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010;74:1191-1197.
5. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders, 2nd ed. Edinburgh; New York: Elsevier/Saunders, 2011.
6. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clinical neuropharmacology 2000;23:75-81.
7. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Movement disorders: official journal of the Movement Disorder Society 2007; 22:1379-1389;quiz 1523.
8. Reimer J, Grabowski M, Lindvall O, Hagell P. Use and interpretation of on/off diaries in Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry2004;75:396-400.
9. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Movement disorders: official journal of the Movement Disorder Society 2010;25:1131 -1142.
10. Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response?Movement disorders: official journal of the Movement Disorder Society 2013;28:341-346.
11. Stacy MA, Murphy JM, Greeley DR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism & related disorders2008;14:205-212.
12. Katzenschlager R, Schrag A, Evans A, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology 2007;69:555-563.
13. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Movement disorders: official journal of the Movement Disorder Society 2005;20 Suppl 11:S11-16.
14. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited-clinical features, natural history, and mortality. Movement disorders: official journal of the Movement Disorder Society 1998;13:885-894.
15. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. The Canadian journal ofneurological sciences. Le journal canadien des sciences neurologiques 1996;23:189-193.
16. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Movement disorders: official journal of the Movement Disorder Society2005;20:342-344.
17. Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of dyskinesia. Movement disorders: official journal of the Movement Disorder Society 2010;25:1177-1182.
18. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Movement disorders: official journal of the Movement Disorder Society 2000;15:459-466.
19. Vidailhet M, Bonnet AM, Marconi R, Gouider-Khouja N, Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology1994;44:1613-1616.
20. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain: a journal of neurology 2003;126:1279-1292.
21. Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain: a journal of neurology 2004;127:1332-1342.
22. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Movement disorders: official journal of the Movement Disorder Society 2003;18:241-253.
23. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Annals of neurology 2001;50:254-257.
24. dela Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain: a journal of neurology 2004;127:888-899.
25. Linazasoro G, Antonini A, Maguire RP, Leenders KL. Pharmacological and PET studies in patients with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications. Journal ofneural transmission2004;111:497-509.
26. Troiano AR, dela Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology2009;72:1211-1216.
27. Hong JY, Oh JS, Lee I, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology2014;82:1597-1604.
28. Linazasoro G, Van Blercom N, Bergaretxe A, Inaki FM, Laborda E, Ruiz Ortega JA. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clinical neuropharmacology 2009;32:326-329.
29. Schneider JS, Gonczi H, Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain research2003;990:38-44.
30. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement disorders: official journal of the Movement Disorder Society 2001;16:448-458.
31. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. The New England journal of medicine 2004;351:2498-2508.
32. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Annals of neurology 2002;52:849-853.
33. Dekker M, Bonifati V, van Swieten J, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Movement disorders: official journal of the Movement Disorder Society 2003;18:751-757.
34. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. The New England journal of medicine2000;342:1484-1491.
35. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Movement disorders: official journal of the Movement Disorder Society 2007;22:2409-2417.
36. Lopez IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson’s disease: ten year followup study. Movement disorders: official journal of the Movement Disorder Society 2010;25:2735-2739.
37. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Archives of neurology2005;62:601-605.
38. Wang J, Liu ZL, Chen B. Association study ofdopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001;56:1757-1759.
39. Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2011;26:73-79.
40. Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry 2009;80:141-144.
41. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson’s disease. The European journal ofneuroscience1994;6:889-897.
42. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Movement disorders: official journal of the Movement Disorder Society 2008;23 Suppl 3:S570-579.
43. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
44. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. Journal ofneurochemistry2003;87:1284-1295.
45. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends in neurosciences 1990;13:290-296.
46. Lewitt PA, Mouradian MM. Predicting the development of levodopa-induced dyskinesias: A presynaptic mechanism? Neurology 2014;82:1574-1575.
47. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature reviews Neuroscience 2001;2:577-588.
48. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature reviews Neuroscience2008;9:665-677.
49. Berthet A, Bezard E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & related disorders 2009; 15 Suppl 4:S8-12.
50. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiological reviews 1998;78:189-225.
51. Le Moine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. The Journal of comparative neurology 1995;355:418-426.
52. Landwehrmeyer B, Mengod G, Palacios JM. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. The European journal of neuroscience 1993;5:145-153.
53. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature medicine2003;9:762-767.
54. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science1990;250:1429-1432.
55. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in neurosciences 1990;13:266-271.
56. Le W, Sayana P, Jankovic J. Animal models of Parkinson’s disease: a gateway to therapeutics? Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2014;11:92-110.
57. Di Chiara G, Morelli M, Barone P, Pontieri F. Priming as a model of behavioural sensitization. Developmental pharmacology and therapeutics 1992;18:223-227.
58. Morelli M, Fenu S, Garau L, Di Chiara G. Time and dose dependence of the ‘priming of the expression of dopamine receptor supersensitivity. European journal of pharmacology 1989;162:329-335.
59. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. The European journal of neuroscience 1998;10:2694-2706.
60. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model ofParkinson's disease. The European journal of neuroscience 2002;15:120-132.
61. Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain: a journal of neurology 2004;127:1661-1669.
62. Gasparini F, Di Paolo T, Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinson’s disease 2013;2013:196028.
63. van Zundert B, Yoshii A, Constantine-Paton M. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends in neurosciences 2004;27:428-437.
64. Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. The European journal ofneuroscience2005;21:3240-3250.
65. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental neurology 2005;196:422-429.
66. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society 2001;16:515-520.
67. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. The Journal ofneuroscience: the official journal of the Society for Neuroscience2006;26:2914-2922.
68. Missale C, Fiorentini C, Busi C, Collo G, Spano PF. The NMDA/D1 receptor complex as a new target in drug development. Current topics in medicinal chemistry 2006;6:801-808.
69. Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006;26:4690-4700.
70. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends in neurosciences 2006;29:647-654.
71. Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. The Journal of neuroscience: the official journal of the Society for Neuroscience2006;26:13548-13555.
72. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson’s disease patients with dyskinesias. Brain: a journal of neurology2004;127:1075-1084.
73. Carta AR, Pinna A, Cauli O, Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 2002;44:166-174.
74. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends in pharmacological sciences2005;26:391-397.
75. Robertson HA, Peterson MR, Murphy K, Robertson GS. D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain research 1989;503:346-349.
76. Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287-294.
77. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proceedings of the National Academy of Sciences of the United States of America1990;87:6912-6916.
78. Calon F, Hadj Tahar A, Blanchet PJ, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends in neurosciences2000;23:S92-100.
79. Dunnett S. L-DOPA, dyskinesia and striatal plasticity. Nature neuroscience 2003;6:437-438.
80. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature neuroscience 2003;6:501-506.
81. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999;23:435-447.
82. Walaas SI, Hemmings HC, Jr., Greengard P, Nairn AC Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases. Frontiers in neuroanatomy 2011;5:50.
83. Morelli M, Cozzolino A, Pinna A, Fenu S, Carta A, Di Chiara G. L-dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. Brain research1993;623:334-336.
84. Steiner H, Gerfen CR. Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. The Journal ofcomparative neurology 1995;353:200-212.
85. Gerfen CR, Keefe KA, Gauda EB. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 1995;15:8167-8176.
86. Robertson GS, Vincent SR, Fibiger HC. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain research 1990;523:288-290.
87. Keefe KA, Gerfen CR. D1 dopamine receptor-mediated induction of zif268 and c-fos in the dopamine-depleted striatum: differential regulation and independence from NMDA receptors. The Journal of comparative neurology 1996;367:165-176.
88. Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. The Journal ofneuroscience: the official journal of the Society for Neuroscience1996;16:4231-4239.
89. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. The Journal of neuroscience: the official journal of the Society for Neuroscience 1998;18:5301-5310.
90. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Annals of neurology1989;25:473-478.
91. Konradi C, Heckers S. Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein. Neuroscience 1995;65:1051-1061.
92. Huang KX, Walters JR. Dopaminergic regulation of AP-1 transcription factor DNA binding activity in rat striatum. Neuroscience 1996;75:757-775.
93. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of neurology 2005;57:17-26.
94. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiology of disease 2007;26:452-463.
95. Berthet A, Porras G, Doudnikoff E, et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. The Journal ofneuroscience: the official journal of the Society for Neuroscience2009;29:4829-4835.
96. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiology of disease 2005;18:323-335.
97. Ahmed MR, Bychkov E, Gurevich VV, Benovic JL, Gurevich EV. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. Journal of neurochemistry2008;104:1622-1636.
98. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 2005;48:503-516.
99. Silverdale MA, Kobylecki C, Hallett PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010;64:177-180.
100. Gross CE, Ravenscroft P, Dovero S, Jaber M, Bioulac B, Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. Journal of neurochemistry 2003;84:1246-1255.
101. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proceedings of the National Academy of Sciences of the United States of America1997;94:3363-3367.
102. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Molecular pharmacology2008;74:59-69.
103. Marcellino D, Ferre S, Casado V, et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. The Journal ofbiological chemistry2008;283:26016-26025.
104. Brambilla R. Targeting Ras/ERK signaling in the striatum: will it help? Molecular psychiatry2003;8:366-368.
105. Valjent E, Pascoli V, Svenningsson P, et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proceedings of the National Academy of Sciences of the United States of America 2005;102:491-496.
106. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biological psychiatry 2007;62:800-810.
107. Morelli M, Di Chiara G. Agonist-induced homologous and heterologous sensitization to D-1-and D-2-dependent contraversive turning. European journal of pharmacology 1987;141:101-107.
108. Calabresi P, Gubellini P, Centonze D, et al. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. The Journal ofneuroscience: the official journal of the Society for Neuroscience2000;20:8443-8451.
109. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine-acetylcholine synaptic balance. Lancet neurology2006;5:974-983.
110. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in neurosciences2007;30:211-219.
111. Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 2003;23:8506-8512.
112. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson’s disease and levodopa-induced dyskinesias. Brain: a journal of neurology 2006;129:1059-1069.
113. Grondin R, Doan VD, Gregoire L, Bedard PJ. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52:771-776.
114. Meissner W, Ravenscroft P, Reese R, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiology of disease 2006;22:586-598.
115. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. Journal of neurochemistry2006;96:1718-1727.
116. dela Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain: a journal of neurology 2004;127:2747-2754.
117. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. Journal of neurochemistry 2006;99:381-392.
118. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson’s disease. Current opinion in neurology 2012;25:448-459.
119. Napolitano M, Picconi B, Centonze D, Bernardi G, Calabresi P, Gulino A. L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neuroscience letters2006;398:211-214.
120. Smith Y, Raju D, Nanda B, Pare JF, Galvan A, Wichmann T. The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain research bulletin2009;78:60-68.
121. Blandini F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson’s disease. Functional neurology 2010;25:65-71.
122. Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatric disease and treatment2013;9:1605-1617.
123. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2000;15:873-878.
124. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology1998;50:1323-1326.
125. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, doubleblind, placebo-controlled study. Parkinsonism & related disorders 2005;11:449-452.
126. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry2004;75:141-143.
127. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of neurology 1999;56:1383-1386.
128. Wolf E, Seppi K, Katzenschlager R, et al. Longterm antidyskinetic efficacy of amantadine in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society2010;25:1357-1363.
129. Jahangirvand AR, A. Early use of amantadine to prevent or delay onset of levodopa-induced dyskinesia in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2013;28:207.
130. Ory-Magne F CJ, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology2014;82:300-307.
131. Pahwa RT, C. Hauser, R. Sethi, K. Isaacson, D. Truong, D. Struck, L. Stempien, M. Went, G. Randomized trial of extended release amantadine in Parkinson’s disease patients with levodopa-induced dyskinesia (EASED study). Movement disorders: official journal of the Movement Disorder Society2013;28:158.
132. Parkinson Study G. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Archives of neurology 2001;58:1660-1668.
133. Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement disorders: official journal of the Movement Disorder Society 2006;21:1380-1383.
134. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology 1998;51:203-206.
135. Pharmaceuticals A. Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients (LID in PD) [online]. Available at: http://clinicaltrials.gov/show/NC T01767129. Accessed April 30, 2014.
136. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study. Clinical neuropharmacology1999;22:273-276.
137. Moreau C, Delval A, Tiffreau V, et al. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. Journal ofneurology, neurosurgery, and psychiatry2013;84:552-555.
138. Vidal EI, Fukushima FB, Valle AP, Villas Boas PJ. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. Journal of the American Geriatrics Society2013;61:170-172.
139. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson’s disease. Experimental neurology 2004;188:471-479.
140. Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Movement disorders: official journal of the Movement Disorder Society 2008;23:1860-1866.
141. Ltd. NP. A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson’s Disease With Levodopa Induced Dyskinesia [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00607451?term=NC T00607451%26rank=1. Accessed April 30, 2014.
142. Picconi B, Calabresi P. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson’s disease?Movement disorders: official journal of the Movement Disorder Society 2014;29:715-719.
143. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson’s disease. Brain research bulletin2006;69:318-326.
144. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. The Journal of pharmacology and experimental therapeutics2010;333:865-873.
145. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neurobiology of disease2008;29:161-168.
146. Gregoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism & related disorders2011;17:270-276.
147. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement disorders: official journal of the Movement Disorder Society 2013;28:1838-1846.
148. Pharmaceuticals N. An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01173731?term=NCT01173731%26rank= 1. Accessed April 30, 2014.
149. Tison FD, Corvol J, Eggert K, Trenkwalder C, Lew, M, Isaacson S, Keywood C, Rascol O. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Neurology 2013;80:004.
150. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54:1589-1595.
151. Eggert K, Squillacote D, Barone P, et al. Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society 2010;25:896-905.
152. Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2012;27:284-288.
153. Rascol O, Barone P, Behari M, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clinical neuropharmacology 2012;35:15-20.
154. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society2003;18:872-883.
155. Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology2012;79:163-169.
156. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg’s archives of pharmacology 2000;361:181-186.
157. Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society2001;16:708-713.
158. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society2000;15:336-337.
159. Buck K, Voehringer P, Ferger B. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of neurochemistry 2010;112:444-452.
160. Hodgson RA, Bedard PJ, Varty GB, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Experimental neurology 2010;225:384-390.
161. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet neurology 2011;10:221-229.
162. Factor SA, Wolski K, Togasaki DM, et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society2013;28:817-820.
163. Jones IW, Bolam JP, Wonnacott S. Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. The Journal ofcomparative neurology 2001;439:235-247.
164. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a doubleblind, placebo-controlled study. Neurology2004;62:381-388.
165. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta neurologica Scandinavica1998;97:295-299.
166. Bennett JP, Jr., Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide longterm dyskinesia reduction. Movement disorders: official journal of the Movement Disorder Society1994;9:409-414.
167. Meco G, Stirpe P, Edito F, et al. Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. Journal of neural transmission2009;116:881-884.
168. Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebocontrolled, trial. Parkinsonism & related disorders2012;18:370-376.
169. Hauser RA, Bronzova J, Sampaio C, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson’s disease. European neurology 2009;62:40-48.
170. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study G. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society2004;19:426-432.
171. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallelgroup trial. Lancet 2005;365:947-954.
172. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Movement disorders: official journal of the Movement Disorder Society2012;27:106-112.
173. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology2004;63:1245-1250.
174. Sugiyama K, Yokoyama T, Namba H. [Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson’s disease patients]. Nihon rinsho Japanese journal of clinical medicine2000;58:2115-2119.
175. Munhoz RP, Cerasa A, Okun MS. Surgical treatment of dyskinesia in Parkinson’s disease. Frontiers in neurology 2014;5:65.
176. Deep-Brain Stimulation for Parkinson’s Disease Study G. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. The New England journal of medicine 2001;345:956-963.
177. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain: a journal of neurology 2005;128:2240-2249.
178. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Annals of neurology 2004;55:871-875.
179. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England journal of medicine2003;349:1925-1934.
180. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. Journal of neurology, neurosurgery, and psychiatry2005;76:1640-1644.
181. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Movement disorders: official journal of the Movement Disorder Society 2006;21 Suppl 14:S290-304.
182. Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet neurology 2013;12:37-44.